'Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM' - Author's reply

Clin Microbiol Infect. 2022 Nov;28(11):1520-1521. doi: 10.1016/j.cmi.2022.06.028. Epub 2022 Jul 4.

Authors

Niklas Broman¹, Thijs Feuth¹, Jarmo Oksi²; COVIDSTORM study group¹

Affiliations

¹ Departments of Infectious Diseases and Pulmonary Diseases, Turku University Hospital, Turku, Finland.
² Departments of Infectious Diseases and Pulmonary Diseases, Turku University Hospital, Turku, Finland. Electronic address: jarmo.oksi@utu.fi.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
COVID-19 Drug Treatment*
Humans
SARS-CoV-2
Treatment Outcome

Substances

tocilizumab
Antibodies, Monoclonal, Humanized